http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112018013227-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ff548dae58eeb810250f8b205c20e20
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y404-01011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-18
filingDate 2017-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b165c962f016ee8d175a39823e5cfff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56404315a761c9f9b7092d4ed80ea0fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9d4903ed533393b123fa3fc7557dc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f3d6a99855262f02ead3178532540ec
publicationDate 2018-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-112018013227-A2
titleOfInvention pharmaceutical compositions or kit for use, methods for treating cancer in a mammal and use of a composition.
abstract The invention relates to a novel method for treating liquid and solid cancers in a mammal, including humans, in which methioninase is administered prior to asparaginase. The invention also encompasses the use of a dietary methionine deprivation possibly combined with methioninase administration prior to asparaginase treatment. methioninase and asparaginase may be used, in particular in free form, pegylated or erythrocyte encapsulated form.
priorityDate 2015-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID246266
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ8RDT4
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6137
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13254
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID66674338
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ7CRG0
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ73KL7
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID41713869
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID374569
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ7MX71
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ8L0X4
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537510
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID104816
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID767799
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ826W3
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A0J6G7P5

Total number of triples: 46.